Graduate School of Systems Life Sciences, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581, Japan,
Cytotechnology. 2007 Dec;55(2-3):55-60. doi: 10.1007/s10616-007-9072-5. Epub 2007 Apr 21.
The use of monoclonal antibodies (mAbs) has now gained a niche as an epochal breakthrough in medicine. Engineered antibodies (Abs) currently account for over 30% of biopharmaceuticals in clinical trials. Several methods to generate human mAbs have evolved, such as (1) immortalization of antigen-specific human B cell hybridoma technology, (2) generation of chimeric and humanized antibody (Ab) from mouse Ab by genetic engineering, (3) acquisition of antigen-specific human B cells by the phage display method, and (4) development of transgenic mice for producing human mAbs. Besides these technologies, we have independently developed a method to generate human mAbs by combining the method of in vitro immunization using peripheral blood mononuclear cells and the phage display method. In this paper, we review the developments in these technologies for generating human mAbs.
单克隆抗体（mAbs）的应用现已成为医学领域的一项重大突破。目前，工程抗体（Abs）占临床试验中生物制药的 30%以上。已经开发出几种生成人 mAbs 的方法，例如：（1）抗原特异性人 B 细胞杂交瘤技术的永生化，（2）通过基因工程从鼠 Ab 生成嵌合和人源化 Ab，（3）通过噬菌体展示方法获得抗原特异性人 B 细胞，以及（4）开发用于产生人 mAbs 的转基因小鼠。除了这些技术之外，我们还独立开发了一种通过结合使用外周血单核细胞的体外免疫和噬菌体展示方法来生成人 mAbs 的方法。在本文中，我们回顾了生成人 mAbs 的这些技术的发展。
